Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

Excision repair cross-complementation group 1 (ERCC1) is one of the key enzymes in DNA repair. This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC).

Methods

Eighty-seven HCC samples were analyzed by immunohistochemistry for ERCC1 and chemosensitivity was assessed by the succinate dehydrogenase inhibition (SDI) test for four anti-cancer agents, including CDDP. The ERCC1 expression was examined in HCC cell lines. ERCC1 siRNA was transfected to PLC/RPF/5 to investigate the correlation of ERCC1 expression and CDDP sensitivity.

Results

ERCC1 expression was observed in 33% of nuclei in immunohistochemical examination. Patients were divided into two groups as follows: ERCC1 high expression group (n = 43): more than 33% of the nuclei were stained; ERCC1 low expression group (n = 44): 33% or fewer of the nuclei were stained. Tumor size of low expression group was larger than that in the high expression group (p = 0.02). The succinic dehydrogenase (SD) activity only for CDDP was significantly higher in the high expression group than that in the low expression group (p = 0.02). An increased expression of ERCC1 was shown by immunohistochemical and Western blot analyses in PLC/RPF/5. ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01).

Conclusions

Increased ERCC1 expression is associated with CDDP resistance in HCC specimens and cell lines. Therefore, immunohistochemical analysis for resected HCC tissues may be a useful predictor for the effectiveness of adjuvant chemotherapy, using CDDP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866–84.

    Article  PubMed  CAS  Google Scholar 

  2. Yamashita Y, Taketomi A, Itoh S, Harimoto N, Morita K, Fukuhra T, Ueda S, Sanefuji K, Sugimachi K, Tajima T, Maehara Y. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009 Jun 3. [Epub ahead of print].

  3. Kawaoka T, Aikata H, Takaki S, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Hieda M, Toyota N, Ito K, Chayama K. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Interv Radiol. 2009;32:687–94.

    Article  PubMed  Google Scholar 

  4. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588–95.

    Article  PubMed  Google Scholar 

  5. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Tanikawa K. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep. 1999;6(3):587–91.

    PubMed  CAS  Google Scholar 

  6. Hamabe ST, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res. 2009;39(3):223–30.

    Article  Google Scholar 

  7. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(1):129–37.

    Article  PubMed  Google Scholar 

  8. De Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem. 1998;273:7835–42.

    Article  PubMed  Google Scholar 

  9. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298–304.

    PubMed  CAS  Google Scholar 

  10. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res. 2002;8:2286–91.

    PubMed  CAS  Google Scholar 

  11. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10:4939–43.

    Article  PubMed  CAS  Google Scholar 

  12. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer. Chest. 2005;127:978–83.

    Article  PubMed  Google Scholar 

  13. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63(6):1311–6.

    PubMed  CAS  Google Scholar 

  14. Gossage L, Madhusudan S. Current status of excision repair cross-complementing group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33(6):565–77.

    Article  PubMed  CAS  Google Scholar 

  15. Liver Cancer Study Group. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara Publications; 2000.

    Google Scholar 

  16. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005;50:211–9.

    Article  PubMed  CAS  Google Scholar 

  17. Takenaka, T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, Shoji F, Maehara Y. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small-cell lung cancer. Int J Cancer. 2007;121:895–900.

    Article  PubMed  CAS  Google Scholar 

  18. Takeuchi H, Baba H, Inutsuka S, Takahashi I, Kusumoto H, Maehara Y, Sugimachi K. Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. Anticancer Res. 1994;14:169–71.

    PubMed  CAS  Google Scholar 

  19. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005;117:376–80.

    Article  PubMed  CAS  Google Scholar 

  20. Itoh S, Taketomi A, Tanaka S, Harimoto N, Yamashita Y, Aishim S, Maeda T, Shirabe K, Shimada M, Maehara Y. Role of growth factor receptor-bound protein 7 in hepatocellular carcinoma. Mol Cancer Res. 2007;5(7):667–73.

    Google Scholar 

  21. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–3.

    Article  PubMed  CAS  Google Scholar 

  22. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, Carter KC, Shell BK, Evans E, de Jong MC, Rademakers S, de Rooij J, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996;86:811–22.

    Article  PubMed  CAS  Google Scholar 

  23. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000;89:453–7.

    Article  PubMed  CAS  Google Scholar 

  24. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007:18(3):504–9.

    Article  PubMed  Google Scholar 

  25. Kondo T, Kubota T, Tanimura H, Yamaue H, Akiyama S, Tanigawa N, Kitajima M, Takagi H. Cumulative results of chemosensitivity tests for antitumor agents in Japan. Japan Research Society for Appropriate Cancer Chemotherapy. Anticancer Res. 2000;20:2389–92.

    PubMed  CAS  Google Scholar 

  26. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.

    Article  PubMed  CAS  Google Scholar 

  27. Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Langouët S. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol. 2005;43(2):288–93.

    Article  PubMed  CAS  Google Scholar 

  28. Andrieux LO, Fautrel A, Bessard A, Guillouzo AL, Baffet G, Sophie L. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res. 2007;67:2114–23.

    Article  PubMed  CAS  Google Scholar 

  29. Tanaka S, Shimada M, Shirabe K, Maehara S, Harimoto N, Tsujita E, Sugimachi K, Maehara Y. A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma. Hepatogastroenterology. 2005;52(63):862–5.

    PubMed  Google Scholar 

  30. Niguma T, Mimura T, Tsutui N. Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. J Hepatobiliary Pancreat Surg. 2005;12:249–53.

    Article  PubMed  Google Scholar 

  31. Abe T, Goda K, Futami K, Furuichi Y. Detection of siRNA administered to cells and animals by using a fluorescence intensity distribution analysis polarization system. Nucleic Acids Res. 2009;37 Suppl 7:e56.

    Article  Google Scholar 

  32. Gondi CS, Rao JS. Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol. 2009;220(2):285–91.

    Article  PubMed  CAS  Google Scholar 

  33. Tam KH, Yang ZF, Lau CK, Lau CT, Pang RWC, Ronnie TP. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Letter. 2009;273:201–9.

    Article  CAS  Google Scholar 

  34. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 2007;31:1465–72.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Shigeru Ueda MD, Ken Shirabe MD, Kazutoyo Morita MD, Kenji Umeda MD, Hiroto Kayashima MD, Hideaki Uchiyama MD, Yuji Soejima MD, Akinobu Taketomi MD & Yoshihiko Maehara MD

Authors
  1. Shigeru Ueda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken Shirabe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazutoyo Morita MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Umeda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroto Kayashima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideaki Uchiyama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuji Soejima MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akinobu Taketomi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshihiko Maehara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken Shirabe MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ueda, S., Shirabe, K., Morita, K. et al. Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma. Ann Surg Oncol 18, 1204–1211 (2011). https://doi.org/10.1245/s10434-010-1414-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1414-4

Keywords

Search

Navigation